Percentile curves for hemoglobin and red cellvolume in infnacy and childhood

Dallman, Peter R.; Siimes, Martti A.

doi:10.1016/s0022-3476(79)80344-3

Cited by 290 publications

(139 citation statements)

References 21 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that infants in our study were younger than the 1-to 2-year age range covered by NHANES surveys. However, we considered NHANES cutoffs to be applicable, since previous research has shown little or no differences in the 6-to 24-month age range for Hb, MCV, FEP, transferrin saturation, or ferritin [42][43][44]. 3.…”

Section: Describing Iron Statusmentioning

confidence: 99%

Iron status of inner‐city African‐American infants

et al. 2006

View full text Add to dashboard Cite

The iron status of African-American infants continues to be subject to debate. We characterized the iron status of 198 9-month-old inner-city infants (94% fed iron-fortified formula) using a comprehensive panel of measures and assessing lead and inflammation markers. The proportion with iron deficiency was calculated based on three approaches (! ! ! ! 2 abnormal iron measures with or without anemia for MCV model-NHANES II, ferritin model-NHANES III, or Sweden/Honduras study) and a promising new measure-body iron, calculated from ferritin and transferrin receptor (TfR). There were no sex differences for any iron measure. Hb < 110 g/l was observed in 25%; Hb 105 g/l in 10.1%. Free erythrocyte protoporphyrin (FEP) values were elevated without elevated lead concentrations or an inflammatory response: mean FEP = 86.6 lg/dl red blood cells [75.5 lmol/mol heme]; 52.3% were > 80 lg/dl (1.42 lmol/l), almost half of which were accompanied by a second abnormal iron measure. The estimated prevalence of iron deficiency was 14.4, 5.3, and 2.5% for the MCV model, ferritin model, and Sweden/Honduras cutoffs, respectively, and 4.1% for body iron < 0 mg/kg. Regulation of iron storage is immature at < 1 year of age, making estimates of iron deficiency that depend on ferritin, including body iron, suspect in this age period. Thus, the ''true'' prevalence of iron deficiency could not be established with confidence due to major differences in the results, depending on the guidelines used. Functional indicators of poor iron status in young infants are urgently needed. Am. J. Hematol. 82:112-121, 2007. V V C 2006 Wiley-Liss, Inc.

show abstract

Section: Describing Iron Statusmentioning

confidence: 99%

Iron status of inner‐city African‐American infants

et al. 2006

View full text Add to dashboard Cite

show abstract

“…29 White blood cell count (WBC) was corrected for the presence of nucleated red blood cells in PB. Reference values for corpuscular volume (MCV) were taken from Dallman and Siimes 30 and for hemoglobin F (HbF) from Huehns and Beaven. 31 Due to the retrospective nature of the study some data could not be retrieved.…”

Section: Introductionmentioning

confidence: 99%

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

et al. 1999

View full text Add to dashboard Cite

We reviewed the clinical features, treatment, and outcome of 100 children with myelodysplastic syndrome (MDS), juvenile myelomonocytic leukemia (JMML), and acute myeloid leukemia (AML) associated with complete monosomy 7 (−7) or deletion of the long arm of chromosome 7 (7q−). Patients with therapyinduced disease were excluded. The morphologic diagnoses according to modified FAB criteria were: MDS in 72 (refractory anemia (RA) in 11, RA with excess of blasts (RAEB) in eight, RAEB in transformation (RAEB-T) in 10, JMML in 43), and AML in 28. The median age at presentation was 2.8 years (range 2 months to 15 years), being lowest in JMML (1.1 year). Loss of chromosome 7 as the sole cytogenetic abnormality was observed in 75% of those with MDS compared with 32% of those with AML. Predisposing conditions (including familial MDS/AML) were found in 20%. Three-year survival was 82% in RA, 63% in RAEB, 45% in JMML, 34% in AML, and 8% in RAEB-T. Children with −7 alone had a superior survival than those with other cytogenetic abnormalities: this was solely due to a better survival in MDS (3-year survival 56 vs 24%). The reverse was found in AML (3-year survival 13% in −7 alone vs 44% in other cytogenetic groups). Stable disease for several years was documented in more than half the patients with RA or RAEB. Patients with RA, RAEB or JMML treated with bone marrow transplantation (BMT) without prior chemotherapy had a 3-year survival of 73%. The morphologic diagnosis was the strongest prognostic factor. Only patients with a diagnosis of JMML fitted what has previously been referred to as the monosomy 7 syndrome. Our data give no support to the concept of monosomy 7 as a distinct syndrome.

show abstract

“…Five of them required no further dose, since their hematocrit values on day +1 were у the normal values that are normal for their ages. 3 The six others received 2 further weeks of treatment of 150 ml/kg rh-Epo three times a week with oral iron supplementation (2.5 mg/kg/twice a day).…”

Section: Resultsmentioning

confidence: 99%

“…The donors were HLA-identical with their sibling recipients. Their baseline hematocrit, reticulocyte count, 3 iron metabolism (serum iron, TIBC, transferrin, serum ferritin) and serum erythropoietin were normal for children of their age. Liver and renal functions and arterial blood pressure were also normal.…”

Section: Methodsmentioning

confidence: 97%

Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors

Martínez

Sastre

Muñoz

et al. 1998

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We have evaluated the efficacy of administering recombinant human erythropoietin (rh-Epo) to 11 healthy bone marrow donors weighing less than 30 kg. Three weeks before harvesting, the donors received 100 units/kg/day rh-Epo subcutaneously and oral iron supplementation (2.5 mg/kg twice daily). Six children with hematocrit values below the normal ranges for their ages after bone marrow harvesting received 150 units/kg rh-Epo three times a week for 2 weeks and oral iron supplementation at the same dose. No rh-Epo sideeffects were observed. Hematocrit values before harvesting increased to between 5.7 and 18.5 (mean 10.6 ± 1.2) above the baseline values (P = 0.0001). Hematocrit after harvesting decreased to between 4 and 19.5% (mean, 11.1) below the day 0 pre-harvest values. On day +15 all but one patient had a hematocrit value уbaseline value. No patient required transfusion during or after bone marrow harvest. Our results show that rh-Epo administration can avoid transfusion and has no side-effects in low weight child bone marrow donors.

show abstract

Percentile curves for hemoglobin and red cellvolume in infnacy and childhood

Cited by 290 publications

References 21 publications

Iron status of inner‐city African‐American infants

Iron status of inner‐city African‐American infants

Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7

Recombinant human erythropoietin (rh-Epo) administration to normal child bone marrow donors

Contact Info

Product

Resources

About